Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.

Abstract: The invention relates to the use of a binding member which binds to Lewisy and Lewisb haptens in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to Lewisy and Lewisb haptens and cancer cells and induces cells death.

Abstract: The expression and subcellular localization of peripheral-type benzodiazepine receptors (PBR) is shown in this application to correlate with the metastatic potential of cells, and increased cell proliferation. Inhibition of PBR expression, function or stability results in a decrease in cell proliferation. Compositions and methods for regulating and/or monitoring PBR and its expression are useful for the detection, diagnosis, prognosis and treatment of solid tumors, in particular, breast cancer.

Abstract: The invention features tumor antigens; tumor antigen-encoding nucleic acids; antibodies specific for tumor antigens and methods of using the antibodies; methods of identifying tumor antigens and the nucleic acids that encode them; methods of monitoring or diagnosing tumors in patients; methods of testing patients for the increased likelihood of developing a tumor; and methods and compositions for treatment of a tumor or prophylaxis against developing a tumor.

Abstract: The invention comprises plasmids and viral vectors containing an animal p53as cDNA sequence. A portion of the p53as sequence may be identified to a position of wild type p53 gene from the same animal. In preferred embodiments, the p53as is mouse or human p53as. A preferred viral vector is baculovirus vector. The invention further includes antibodies both polyclonal and monoclonal, to p53as and to at least a portion of human p53 intron 10 sequence encoding SLRPFKALVREKGHRPSSHSC (SEQ. I.D. NO. 1) which is related to p53as sequences and plasmids and viral vectors containing such sequences. All of the above find utility in studying p53 and p53as and their relative expressions which is believed important for detection and control of malignant cells and their susceptibility to treatment agents.

Abstract: To provide a screening method for an apoptosis-suppressing substance or an apoptosis-promoting substance, the application of which substances to pharmaceuticals or diagnostic drugs are expected, also to provide an apoptosis-suppressing substance or an apoptosis-promoting substance, since Bcl-2 family having apoptosis-suppressing or -promoting activities is deeply involved in many diseases. To attain the above object, VDAC-liposomes, an indicator substance such as fluorescent-labeled cytochrome c or isotope-labeled sucrose etc. capable of passing through VDAC (voltage-dependent anion channel), and a subject substance are incubated, and then concentration changes in the indicator substance, inside and outside the VDAC-liposomes before and after the incubation, are detected in order to estimate presence or absence of the apoptosis-suppressing activity or -promoting activity of the subject substance.

Abstract: A novel gene, PB39, that is up-regulated, or over-expressed, in prostate cancer has been identified. The gene has been identified by means of its cDNA obtained by reverse transcription of the corresponding mRNA. Microdissection of prostate glands that had been surgically removed from prostate cancer patients revealed a novel up-regulated transcript in an aggressive prostate carcinoma. Differential analysis for the presence of this gene was carried out from the same glands by comparing transcription in microdissected normal prostatic epithelium versus that in microdissected invasive tumor. The transcript was over-expressed in 5 of 10 prostate carcinomas examined. A variant transcript was over-expressed in 4 of 4 prostate carcinomas, and was found in 1 of 4 normal samples.

Abstract: A novel gene (designated 101P3A11 and also referred to as PHOR-1) and its encoded protein are described. While 101P3A11 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in prostate, colon and kidney cancers. Thus, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

Abstract: The present invention provides an isolated nucleic acid molecule comprising sequences encoding the CA125 protein or a portion thereof. This invention also provides a method to detect ovarian cancer in a subject. Furthermore, this invention provides a method for the diagnosis of a cancer which expresses CA125 by detecting CA125-expressing cells in the blood or other fluids of patients. This invention also provides a method of producing CA125 protein. This invention also provides a method of silencing CA125 protein production. Finally, this invention provides a method to treat or prevent cancer using a vaccine comprising CA125 nucleic acid or protein.

Abstract: The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the brain, lung, breast, prostate and colon. The method comprises contacting a cancer cell with a molecule that disrupts the biological activity of a GDOX molecule. In one embodiment, the molecule is an antibody directed against a GDOX peptide. In other embodiments, the molecule is an antisense nucleotide directed against a GDOX nucleic acid molecule, or a vaccine comprising a GDOX peptide or a polynucleotide encoding a GDOX peptide. The invention additionally provides methods for detecting and treating cancer using GDOX-related molecules.

Abstract: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell proliferation and in particular cancer.

Abstract: Novel forms of mutant BAD polypeptides or fragments thereof having amino acid substitutions for serine-155 are provided along with their encoding polynucleotides. Also disclosed are methods for preparation of the mutant BAD polypeptides, methods for screening candidate compounds and drugs for activity that promotes cell survival or apoptosis, methods for screening candidate compounds and drugs for phosphatase activity capable of dephosphorylating BAD, methods for screening candidate compounds and drugs for kinase activity capable of phosphorylating BAD, methods for screening candidate compounds and drugs for activity that promotes phosphorylation of BAD, anti-BAD antibodies, and methods for inhibiting and inducing apoptosis.

Abstract: The invention provides novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, antibodies, and modulatory compounds for use in methods of diagnosing, treating, and preventing diseases and conditions of the prostate and testis, such as cancer.

Abstract: An isolated nucleic acid sequence of a mitotic checkpoint gene, chfr, encodes a Chfr protein having a Forkhead-associated domain and a Ring Finger. This protein is required for regulation of the transition of cells from prophase to metaphase during mitosis. The chfr nucleic acid and Chfr polypeptide are useful in diagnosing tumorigenic cells and in screening for drugs which can inhibit the activity of Chfr in a cancer cell, thereby rendering the cell more sensitive to additional anti-tumor therapies.

Abstract: The present invention describes the identification, isolation and characterization of novel mammalian proteins encoded by the Ese1 and Ese2 genes which are involved in endocytosis, vesicular trafficking and regulation of the actin cytoskeleton. Transcripts and products of these genes are useful for detecting abnormal cellular endocytosis processes as well as for developing assay systems to find and elucidate further binding partners of the proteins, to develop therapeutics to alter/restore protein function and for the isolation and manufacture of Ese proteins.

Abstract: The present invention is directed to a method for determining whether a woman has, or is likely to develop, ovarian cancer based upon assays of the alpha subunit of haptoglobin.

Abstract: Activated lymphocytes are administered to a cancer patient at least five or more times within eight months after performing surgical and chemotherapeutic treatment or radiotherapy for treating cancer particularly liver cancer, so that recurrence of the cancer can be prevented over a long period of five or more years. The activated lymphocytes to be administered while performing treatment of cancer may be autologously derived from a cancer patient or collected from the other cancer patient at need. The activated lymphocytes can be cultivated for proliferating or activating lymphocyte cells collected in the presence of solid-phase anti-CD3 antigen and interleukin 2.

Abstract: This invention provides compositions derived from the sequences encoding the variable light and/or variable heavy regions of monoclonal anti-idiotype antibody 3H1 and methods for using these compositions.

Abstract: The present invention relates to novel human apoptosis related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human apoptosis related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human apoptosis related polypeptides.

Abstract: The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided.